First-generation  ||| S:0 E:17 ||| JJ
antipsychotic  ||| S:17 E:31 ||| JJ
long-acting  ||| S:31 E:43 ||| JJ
injections  ||| S:43 E:54 ||| NNS
v.  ||| S:54 E:57 ||| CC
oral  ||| S:57 E:62 ||| JJ
antipsychotics  ||| S:62 E:77 ||| NN
in  ||| S:77 E:80 ||| IN
schizophrenia ||| S:80 E:93 ||| NN
:  ||| S:93 E:95 ||| :
systematic  ||| S:95 E:106 ||| JJ
review  ||| S:106 E:113 ||| NN
of  ||| S:113 E:116 ||| IN
randomised  ||| S:116 E:127 ||| JJ
controlled  ||| S:127 E:138 ||| JJ
trials  ||| S:138 E:145 ||| NNS
and  ||| S:145 E:149 ||| CC
observational  ||| S:149 E:163 ||| JJ
studies  ||| S:163 E:171 ||| NNS
Antipsychotic  ||| S:171 E:185 ||| JJ
long-acting  ||| S:185 E:197 ||| JJ
injections  ||| S:197 E:208 ||| NNS
( ||| S:208 E:209 ||| -LRB-
LAIs ||| S:209 E:213 ||| NNP
)  ||| S:213 E:215 ||| -RRB-
are  ||| S:215 E:219 ||| VBP
often  ||| S:219 E:225 ||| RB
used  ||| S:225 E:230 ||| VBN
in  ||| S:230 E:233 ||| IN
an  ||| S:233 E:236 ||| DT
attempt  ||| S:236 E:244 ||| NN
to  ||| S:244 E:247 ||| TO
improve  ||| S:247 E:255 ||| VB
medication  ||| S:255 E:266 ||| JJ
adherence  ||| S:266 E:276 ||| NN
in  ||| S:276 E:279 ||| IN
people  ||| S:279 E:286 ||| NNS
with  ||| S:286 E:291 ||| IN
schizophrenia ||| S:291 E:304 ||| NN
.  ||| S:304 E:306 ||| .
To  ||| S:306 E:309 ||| TO
compare  ||| S:309 E:317 ||| VB
first-generation  ||| S:317 E:334 ||| JJ
antipsychotic  ||| S:334 E:348 ||| JJ
long-acting  ||| S:348 E:360 ||| JJ
injections  ||| S:360 E:371 ||| NNS
( ||| S:371 E:372 ||| -LRB-
FGA-LAIs ||| S:372 E:380 ||| NNP
)  ||| S:380 E:382 ||| -RRB-
with  ||| S:382 E:387 ||| IN
first-  ||| S:387 E:394 ||| JJ
and  ||| S:394 E:398 ||| CC
second-generation  ||| S:398 E:416 ||| JJ
oral  ||| S:416 E:421 ||| JJ
antipsychotics  ||| S:421 E:436 ||| NN
in  ||| S:436 E:439 ||| IN
terms  ||| S:439 E:445 ||| NNS
of  ||| S:445 E:448 ||| IN
clinical  ||| S:448 E:457 ||| JJ
outcome ||| S:457 E:464 ||| NN
.  ||| S:464 E:466 ||| .
Systematic  ||| S:466 E:477 ||| JJ
literature  ||| S:477 E:488 ||| NN
review ||| S:488 E:494 ||| NN
.  ||| S:494 E:496 ||| .
A  ||| S:496 E:498 ||| DT
meta-analysis  ||| S:498 E:512 ||| JJ
of  ||| S:512 E:515 ||| IN
randomised  ||| S:515 E:526 ||| JJ
controlled  ||| S:526 E:537 ||| JJ
trials  ||| S:537 E:544 ||| NNS
( ||| S:544 E:545 ||| -LRB-
RCTs ||| S:545 E:549 ||| NNP
)  ||| S:549 E:551 ||| -RRB-
showed  ||| S:551 E:558 ||| VBD
no  ||| S:558 E:561 ||| DT
difference  ||| S:561 E:572 ||| NN
in  ||| S:572 E:575 ||| IN
relapse  ||| S:575 E:583 ||| NN
or  ||| S:583 E:586 ||| CC
tolerability  ||| S:586 E:599 ||| NN
between  ||| S:599 E:607 ||| IN
oral  ||| S:607 E:612 ||| JJ
antipsychotics  ||| S:612 E:627 ||| NN
and  ||| S:627 E:631 ||| CC
FGA-LAIs  ||| S:631 E:640 ||| JJ
but  ||| S:640 E:644 ||| CC
global  ||| S:644 E:651 ||| JJ
improvement  ||| S:651 E:663 ||| NN
was  ||| S:663 E:667 ||| VBD
twice  ||| S:667 E:673 ||| RB
as  ||| S:673 E:676 ||| IN
likely  ||| S:676 E:683 ||| JJ
with  ||| S:683 E:688 ||| IN
FGA-LAIs ||| S:688 E:696 ||| JJ
.  ||| S:696 E:698 ||| .
Four  ||| S:698 E:703 ||| CD
prospective  ||| S:703 E:715 ||| JJ
observational  ||| S:715 E:729 ||| JJ
studies  ||| S:729 E:737 ||| NNS
were  ||| S:737 E:742 ||| VBD
identified ||| S:742 E:752 ||| VBN
;  ||| S:752 E:754 ||| :
two  ||| S:754 E:758 ||| CD
studies  ||| S:758 E:766 ||| NNS
reported  ||| S:766 E:775 ||| VBD
lower  ||| S:775 E:781 ||| JJR
discontinuation  ||| S:781 E:797 ||| NN
rates  ||| S:797 E:803 ||| NNS
for  ||| S:803 E:807 ||| IN
FGA-LAIs  ||| S:807 E:816 ||| JJ
compared  ||| S:816 E:825 ||| VBN
with  ||| S:825 E:830 ||| IN
oral  ||| S:830 E:835 ||| JJ
medication  ||| S:835 E:846 ||| NN
and  ||| S:846 E:850 ||| CC
two  ||| S:850 E:854 ||| CD
found  ||| S:854 E:860 ||| VBD
that  ||| S:860 E:865 ||| DT
outcome  ||| S:865 E:873 ||| NN
was  ||| S:873 E:877 ||| VBD
either  ||| S:877 E:884 ||| RB
no  ||| S:884 E:887 ||| DT
different  ||| S:887 E:897 ||| JJ
or  ||| S:897 E:900 ||| CC
better  ||| S:900 E:907 ||| JJR
with  ||| S:907 E:912 ||| IN
oral  ||| S:912 E:917 ||| JJ
antipsychotics ||| S:917 E:931 ||| NN
.  ||| S:931 E:933 ||| .
Mirror-image  ||| S:933 E:946 ||| JJ
studies  ||| S:946 E:954 ||| NNS
consistently  ||| S:954 E:967 ||| RB
showed  ||| S:967 E:974 ||| VBD
reduced  ||| S:974 E:982 ||| VBN
in-patient  ||| S:982 E:993 ||| JJ
days  ||| S:993 E:998 ||| NNS
and  ||| S:998 E:1002 ||| CC
admissions  ||| S:1002 E:1013 ||| NNS
following  ||| S:1013 E:1023 ||| VBG
a  ||| S:1023 E:1025 ||| DT
switch  ||| S:1025 E:1032 ||| NN
from  ||| S:1032 E:1037 ||| IN
oral  ||| S:1037 E:1042 ||| JJ
antipsychotics  ||| S:1042 E:1057 ||| NN
to  ||| S:1057 E:1060 ||| TO
FGA-LAIs ||| S:1060 E:1068 ||| JJ
.  ||| S:1068 E:1070 ||| .
The  ||| S:1070 E:1074 ||| DT
results  ||| S:1074 E:1082 ||| NNS
are  ||| S:1082 E:1086 ||| VBP
variable  ||| S:1086 E:1095 ||| JJ
and  ||| S:1095 E:1099 ||| CC
inconclusive ||| S:1099 E:1111 ||| JJ
.  ||| S:1111 E:1113 ||| .
Some  ||| S:1113 E:1118 ||| DT
evidence  ||| S:1118 E:1127 ||| NN
suggests  ||| S:1127 E:1136 ||| VBZ
that  ||| S:1136 E:1141 ||| DT
FGA-LAIs  ||| S:1141 E:1150 ||| NN
may  ||| S:1150 E:1154 ||| MD
improve  ||| S:1154 E:1162 ||| VB
outcome  ||| S:1162 E:1170 ||| NN
compared  ||| S:1170 E:1179 ||| VBN
with  ||| S:1179 E:1184 ||| IN
oral  ||| S:1184 E:1189 ||| JJ
antipsychotics ||| S:1189 E:1203 ||| NN
.  ||| S:1203 E:1205 ||| .
Methodological  ||| S:1205 E:1220 ||| JJ
issues  ||| S:1220 E:1227 ||| NNS
may  ||| S:1227 E:1231 ||| MD
partly  ||| S:1231 E:1238 ||| RB
explain  ||| S:1238 E:1246 ||| VB
the  ||| S:1246 E:1250 ||| DT
variable  ||| S:1250 E:1259 ||| JJ
results ||| S:1259 E:1266 ||| NNS
.  ||| S:1266 E:1268 ||| .
Selective  ||| S:1268 E:1278 ||| JJ
recruitment  ||| S:1278 E:1290 ||| NN
in  ||| S:1290 E:1293 ||| IN
RCTs  ||| S:1293 E:1298 ||| JJ
and  ||| S:1298 E:1302 ||| CC
lack  ||| S:1302 E:1307 ||| NN
of  ||| S:1307 E:1310 ||| IN
randomisation  ||| S:1310 E:1324 ||| NN
in  ||| S:1324 E:1327 ||| IN
observational  ||| S:1327 E:1341 ||| JJ
studies  ||| S:1341 E:1349 ||| NNS
are  ||| S:1349 E:1353 ||| VBP
biases  ||| S:1353 E:1360 ||| VBN
against  ||| S:1360 E:1368 ||| IN
LAIs ||| S:1368 E:1372 ||| NNP
,  ||| S:1372 E:1374 ||| ,
whereas  ||| S:1374 E:1382 ||| IN
regression  ||| S:1382 E:1393 ||| VBG
to  ||| S:1393 E:1396 ||| TO
the  ||| S:1396 E:1400 ||| DT
mean  ||| S:1400 E:1405 ||| NN
in  ||| S:1405 E:1408 ||| IN
mirror-image  ||| S:1408 E:1421 ||| JJ
studies  ||| S:1421 E:1429 ||| NNS
favours  ||| S:1429 E:1437 ||| VBP
LAIs ||| S:1437 E:1441 ||| JJ
.  ||| S:1441 E:1443 ||| .
In  ||| S:1443 E:1446 ||| IN
terms  ||| S:1446 E:1452 ||| NNS
of  ||| S:1452 E:1455 ||| IN
future  ||| S:1455 E:1462 ||| JJ
research ||| S:1462 E:1470 ||| NN
,  ||| S:1470 E:1472 ||| ,
a  ||| S:1472 E:1474 ||| DT
long-term  ||| S:1474 E:1484 ||| JJ
pragmatic  ||| S:1484 E:1494 ||| JJ
RCT  ||| S:1494 E:1498 ||| NN
of  ||| S:1498 E:1501 ||| IN
an  ||| S:1501 E:1504 ||| DT
FGA-LAI  ||| S:1504 E:1512 ||| JJ
against  ||| S:1512 E:1520 ||| IN
an  ||| S:1520 E:1523 ||| DT
oral  ||| S:1523 E:1528 ||| JJ
antipsychotic ||| S:1528 E:1541 ||| NN
,  ||| S:1541 E:1543 ||| ,
in  ||| S:1543 E:1546 ||| IN
patients  ||| S:1546 E:1555 ||| NNS
with  ||| S:1555 E:1560 ||| IN
problematic  ||| S:1560 E:1572 ||| JJ
adherence ||| S:1572 E:1581 ||| NN
,  ||| S:1581 E:1583 ||| ,
would  ||| S:1583 E:1589 ||| MD
be  ||| S:1589 E:1592 ||| VB
of  ||| S:1592 E:1595 ||| IN
value ||| S:1595 E:1600 ||| NN
.  ||| S:1600 E:1602 ||| .
